Modern at-home allergy immunotherapy that replaces years of in-office shots
Modern at-home allergy immunotherapy that replaces years of in-office shots is a SaaS business listed at $2,899,611 on Acquire, in telehealth, healthcare. It reports $-91,869 of annual profit, a 1.30x rev multiple. Acquisiteur has tracked this listing since Sep 5, 2026 and its status is still live. Comparable SaaS businesses close at a median 3.60x annual profit.
First seen Sep 5, 2026 · last checked 23 hours ago
- Asking price
- $2,899,611
- Annual profit
- $-91,869
- Annual revenue
- $2,230,471
- Revenue multiple
- 1.30x rev
- Monthly profit
- $-7,656
- Age
- 5 yrs
Confidence in this listing
Enough to judge the shape of it, not enough to price it.
47/100
- What is documented
- Trading for 5 years
- Tracked here for 1 month(s)
- What to ask about
- Listed through a marketplace, figures as supplied
- No profit figure
This scores the paperwork, not the business. Acquire: listed through a marketplace, figures as supplied. Always verify the figures with the seller before making an offer.
Overview
This is a national telehealth platform focused on physician-guided, at-home allergy immunotherapy via a subscription model, helping patients access long-term, disease-modifying treatment without frequent in-office visits, while operating a fully compliant infrastructure licensed across all 50 states with integrated clinical, pharmacy, and technology workflows that support durable recurring revenue through multi-year treatment durations, strong retention, and efficient customer acquisition, alongside a rapidly scaling B2B channel that enables medical practices to offer allergy treatment without added operational complexity in a large, underserved chronic-care market. Key Highlights ✅ Modern at-home allergy immunotherapy delivered through a subscription model with physician oversight ✅ Fully compliant infrastructure licensed across all 50 states with integrated clinical, pharmacy, and technology workflows ✅ Durable recurring revenue supported by multi-year treatment durations, strong retention, and efficient customer acquisition ✅ Rapidly scaling B2B channel that enables medical practices to offer allergy treatment without added operational complexity ✅ Scalable, capital-efficient platform serving a large, underpenetrated segment of chronic care with long-term growth potential
Price & status history
- ListedSep 5, 2026
Get new SaaS businesses like this one, every morning
One email a day with what just listed across every marketplace, priced against real closed sales. Free, no card.
Similar live deals
- Restaurant POS and delivery management software company$3.2M3.64x
- B2B SaaS cybersecurity awareness and training platform$1.2M2.01x
- Profitable Automated Social Media Saas In California$1.3M5.89x
- Profitable B2B Cold Email Infrastructure SaaS — $1.63M TTM Revenue, $868K Profit$2.9M3.40x
- B2B SaaS platform for hospitality supply chain management$5M5.04x
- Customer Acquisition Software Platform$4.5M8.89x